Axial spondyloarthritis

axial-spondyloarthritis · society: ACR/SAA/SPARTAN

← back to Rheumatology

Summary

2019 ACR/SAA/SPARTAN update of the 2015 recommendations for treatment of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), focused on positioning of newer agents (secukinumab, ixekizumab, tofacitinib, TNFi biosimilars) and the role of imaging. NSAIDs and TNFi remain first-line pharmacologic therapy; IL-17 inhibitors are preferred over a second TNFi in primary TNFi non-responders, while a second TNFi is preferred for secondary non-response. New recommendations address against treat-to-target with ASDAS, against routine biologic tapering/discontinuation in stable disease, against mandated switching to a biosimilar, and against scheduled serial spine radiographs.

Current guideline: ACR/SAA/SPARTAN 2019 Axial Spondyloarthritis Guideline · download Anki sub-deck

Versions

• 2019 · ACR/SAA/SPARTAN — ACR/SAA/SPARTAN 2019 Axial Spondyloarthritis Guideline
  • Read the guideline: html · pmc · Anki deck

---

Table of contents

• 2019 · ACR/SAA/SPARTAN